HCV Treatment
CROI 2015: Re-infection Due to Ongoing Risk Is Probably the Cause of HCV Recurrence After SVR
- Details
- Category: HCV Treatment
- Published on Friday, 13 March 2015 00:00
- Written by Michael Carter
Rates of hepatitis C virus (HCV) recurrence after successful therapy differ markedly between risk groups, according to the results of a meta-analysis presented at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.
CROI 2015: Sustained Virological Response Represents a Long-term Cure for Hepatitis C
- Details
- Category: HCV Treatment
- Published on Friday, 13 March 2015 00:00
- Written by Liz Highleyman
Almost all patients with hepatitis C virus alone or HIV/HCV coinfection who achieved sustained virological response (SVR) to treatment with sofosbuvir (Sovaldi) plus ribavirin or sofosbuvir/ledipasvir (Harvoni) still had undetectable HCV RNA up to 2.4 years later, confirming that SVR represents a cure, according to a poster presented at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.
Coverage of the 2015 Conference on Retroviruses and Opportunistic Infections
- Details
- Category: HIV Treatment
- Published on Monday, 02 March 2015 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 2015 Conference on Retroviruses and Opportunistic infections (CROI 2015), February 23-26, 2015, in Seattle.
Conference highlights include PrEP and HIV treatment as prevention, hepatitis C treatment for HIV/HCV coinfected people, new antiretroviral drugs, HIV cure research, HIV-related conditions, TB, Ebola virus, and access to care.
HIVandHepatitis.com coverage by topic
3/2/15
CROI 2015: Hepatitis C -- Mission Accomplished? [VIDEO]
- Details
- Category: HCV Treatment
- Published on Friday, 06 March 2015 00:00
- Written by Gregory Fowler
New interferon-free treatment for hepatitis C virus (HCV) has brought about a revolution in treatment, but challenges still remain -- among them too few people with HCV being diagnosed and the high cost of the new drugs -- before the mission can be declared a success. A panel of hepatitis C experts discuss research presented at the recent 2015 Conference on Retroviruses and Opportunistic Infections(CROI) in Seattle with HIVandHepatitis.com editor Liz Highleyman in this IFARA video.
New Hepatitis C Treatments Highly Effective for HIV/HCV Coinfected People
- Details
- Category: HCV Treatment
- Published on Tuesday, 24 February 2015 00:00
- Written by Liz Highleyman
A pair of interferon-free combinations -- AbbVie's 3-drug Viekira Pak regimen and Gilead Science's sofosbuvir/ledipasvir (Harvoni) -- demonstrated good safety and cured more than 90% of genotype 1 HIV/HCV coinfected people, according to studies published in the February 23 advance edition of the Journal of the American Medical Association.
Web Design and Development by